Beyond the framework
Things we were not explicitly looking for — unexpected observations, newly raised issues and emerging patterns that surfaced in the conversations outside the predefined KBQ and KIQ framework. Presented as additional observations, not established trends.
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Several conversations touched on affordability, reimbursement and access as factors that shape what clinicians can realistically offer, independent of the clinical data — a topic none of the predefined questions asked about.
7
of 16 conversations
Why it may matter
Access considerations may moderate the real-world uptake implied by the clinical enthusiasm seen in the KBQ analysis.
Patient-reported outcomes and day-to-day functioning were raised repeatedly, unprompted, as increasingly central to treatment decisions in this setting.
9
of 16 conversations
Why it may matter
Quality-of-life framing appears influential across questions and may be underweighted relative to efficacy endpoints in current materials.
A number of experts spontaneously referenced molecular profiling and ctDNA as an emerging lens for selecting and sequencing therapy.
6
of 16 conversations
Why it may matter
Biomarker-guided reasoning may become a key frame for future positioning and warrants monitoring.
Some clinicians expressed unprompted frustration at being asked to compare treatments across trials with differing populations and designs.
5
of 16 conversations
Why it may matter
A desire for fair, like-for-like comparison could shape how comparative messaging is received.
Decisions were frequently described as team-based, with the MDT influencing whether and how a new option is taken up — a dynamic not captured by the KBQs.
8
of 16 conversations
Why it may matter
Adoption may depend on MDT-level acceptance rather than individual prescriber preference alone.
Concern that trial populations are healthier and more selected than the patients seen in routine practice recurred across conversations without being asked.
7
of 16 conversations
Why it may matter
Perceived generalisability gaps could temper how readily trial results translate into practice.